These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38131223)

  • 21. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
    Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
    Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Simbault L; Abadie J; Loussouarn D; Campone M; Nguyen F
    Tumour Biol; 2020 Jan; 42(1):1010428319901052. PubMed ID: 31959092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
    Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
    Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Surgical wounding enhances pro-tumor macrophage responses and accelerates tumor growth and lung metastasis in a triple negative breast cancer mouse model.
    McDonald SJ; VanderVeen BN; Bullard BM; Cardaci TD; Madero SS; Chatzistamou I; Fan D; Murphy EA
    Physiol Rep; 2022 Nov; 10(21):e15497. PubMed ID: 36325601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.
    Dattilo R; Mottini C; Camera E; Lamolinara A; Auslander N; Doglioni G; Muscolini M; Tang W; Planque M; Ercolani C; Buglioni S; Manni I; Trisciuoglio D; Boe A; Grande S; Luciani AM; Iezzi M; Ciliberto G; Ambs S; De Maria R; Fendt SM; Ruppin E; Cardone L
    Cancer Res; 2020 Oct; 80(19):4087-4102. PubMed ID: 32718996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models.
    Baptista Moreno Martin AC; Tomasin R; Luna-Dulcey L; Graminha AE; Araújo Naves M; Teles RHG; da Silva VD; da Silva JA; Vieira PC; Annabi B; Cominetti MR
    Cell Oncol (Dordr); 2020 Oct; 43(5):915-929. PubMed ID: 32761561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
    Wolfson B; Padget MR; Schlom J; Hodge JW
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
    Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J
    Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
    Norton KA; Wallace T; Pandey NB; Popel AS
    BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
    Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
    Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
    Demeule M; Charfi C; Currie JC; Larocque A; Zgheib A; Kozelko S; Béliveau R; Marsolais C; Annabi B
    Cancer Sci; 2021 Oct; 112(10):4317-4334. PubMed ID: 34314556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitro-fatty acid inhibition of triple-negative breast cancer cell viability, migration, invasion, and tumor growth.
    Woodcock CC; Huang Y; Woodcock SR; Salvatore SR; Singh B; Golin-Bisello F; Davidson NE; Neumann CA; Freeman BA; Wendell SG
    J Biol Chem; 2018 Jan; 293(4):1120-1137. PubMed ID: 29158255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.